Filed Pursuant to Rule 424(b)(5)
Registration No. 333-256850
Prospectus Supplement
(To Prospectus dated October 22, 2021)
3,284,407 Shares
of Common Stock
Pre-funded warrants to purchase 2,919,140
Shares of Common Stock
We are offering 3,284,407
shares of our common stock and, in lieu of common stock, pre-funded warrants to purchase 2,919,140 shares of our common stock,
in a registered direct offering to a limited number of purchasers pursuant to this prospectus supplement and the accompanying prospectus.
The purchase price of each pre-funded warrant equals the price per share at which shares of our common stock are being sold in this offering,
minus $0.0001, and the exercise price of each pre-funded warrant equals $0.0001 per share. This prospectus supplement also relates to
the offering of the shares of common stock issuable upon exercise of such pre-funded warrants.
Our common stock is listed
on the Nasdaq Capital Market under the symbol “ABEO.” On June 30, 2023, the last reported sales price for our common
stock on the Nasdaq Capital Market was $4.03 per share. We do not intend to list the pre-funded warrants on the Nasdaq Capital
Market, any other national securities exchange or any other nationally recognized trading system.
We engaged Cantor
Fitzgerald & Co. to act as our sole lead-placement agent and A.G.P./Alliance Global Partners as co-placement agent in
connection with this offering. The placement agents are not purchasing the securities in this offering and are not
required to arrange the purchase or sale of any specific number or dollar amount of securities.
Investing in our securities involves
significant risks. Please read the information contained in or incorporated by reference under the heading “Risk Factors”
beginning on page S-5 of this prospectus supplement, and under similar headings in other documents filed after the date hereof
and incorporated by reference into this prospectus supplement and the accompanying prospectus.
Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy
of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
| |
Per Share | | |
Per Pre-Funded Warrant | | |
Total | |
Offering price | |
$ | 4.0300 | | |
$ | 4.0299 | | |
$ | 25,000,002 | |
Placement agent fees(1) | |
$ | 0.2821 | | |
$ | 0.2821 | | |
$ | 1,750,000 | |
Proceeds to Abeona Therapeutics Inc., before expenses(2) | |
$ | 3.7479 | | |
$ | 3.7478 | | |
$ | 23,250,002 | |
| (1) | See the section
titled “Plan of Distribution” for additional disclosure regarding the placement
agent fees. |
| (2) | The above summary of offering proceeds does not give effect
to any proceeds from the exercise of the pre-funded warrants being delivered in this offering. |
Delivery of the shares
of common stock and pre-funded warrants is expected to be made on or about July 6, 2023.
Sole Lead-Placement Agent
Cantor
Co-Placement Agent
A.G.P.
The date of this prospectus supplement
is July 3, 2023
TABLE OF CONTENTS
Prospectus Supplement
Prospectus
ABOUT THIS PROSPECTUS SUPPLEMENT
This prospectus supplement and the accompanying
prospectus relate to the offering of our common stock and pre-funded warrants. You should read this prospectus supplement, the accompanying
prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and any free writing
prospectus that we may authorize for use in connection with this offering in their entirety before making an investment decision. You
should also read and consider the information in the documents to which we have referred you in the section of this prospectus supplement
entitled “Where You Can Find More Information; Incorporation by Reference.” These documents contain important information
that you should consider when making your investment decision.
This document is in two parts. The first
part is this prospectus supplement, which describes the specific terms of the offering of the common stock and pre-funded warrants and
also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus
supplement and the accompanying prospectus. The second part, the accompanying prospectus, including the documents incorporated by reference
into the accompanying prospectus, provides more general information, some of which may not apply to this offering. Generally, when we
refer to this prospectus, we are referring to the combined document consisting of this prospectus supplement and the accompanying prospectus.
To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information
contained in the accompanying prospectus or in any document incorporated by reference into the accompanying prospectus that was filed
with the Securities and Exchange Commission (the “SEC”) before the date of this prospectus supplement, on the other hand,
you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement
in another document having a later date, the statement in the document having the later date modifies or supersedes the earlier statement.
We are responsible for
the information contained in, or incorporated by reference into, this prospectus supplement, the accompanying prospectus and in any free
writing prospectus that we may authorize for use in connection with this offering. We have not, and the placement agents have
not, authorized any other person to provide you with different information, and neither we nor the placement agents take any responsibility
for any other information that others may give you.
We are not, and the
placement agents are not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction in
which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so
or to anyone to whom it is unlawful to make an offer or solicitation.
You should assume that the information
appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus supplement
and the accompanying prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering is
accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may
have changed since those dates.
Unless the context otherwise requires
or as otherwise expressly stated, references in this prospectus to the terms “the Company,” “Abeona,” “we,”
“our” and “us” or other similar terms mean Abeona Therapeutics Inc. and its subsidiaries.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement, the accompanying
prospectus, and the other documents we have filed with the SEC that are incorporated herein by reference contain forward-looking statements
that involve substantial risks and uncertainties. All statements, other than statements of historical facts, regarding our strategy,
future operations, future financial position, future revenues, projected costs, prospects, plans, objectives of management or other financial
items are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,”
“seek,” “intend,” “may,” “plan,” “predict,” “project,” “will,”
“would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements
contain these identifying words.
We may not actually achieve the plans,
intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking
statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking
statements we make. We have included important factors in the cautionary statements included in this prospectus supplement, particularly
as set forth and incorporated by reference in the “Risk Factors” section, that we believe could cause actual results or events
to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact
of any future acquisitions, mergers, dispositions, joint ventures, collaborations, or investments we may make. You should read this prospectus
supplement, the accompanying prospectus, and the documents that we incorporate by reference in this prospectus supplement completely
and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation
to update any forward-looking statements, except as otherwise required by law. We advise you, however, to consult any further disclosures
we make on related subjects in our future annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K
we file with the SEC.
SUMMARY
This summary highlights information
contained elsewhere or incorporated by reference in this prospectus supplement and the accompanying prospectus. This summary does not
contain all of the information that you should consider before deciding to invest in our securities. You should read this entire prospectus
supplement and the accompanying prospectus carefully, including the “Risk Factors” section beginning on page S-5 of
this prospectus supplement, our financial statements and the related notes thereto and the other documents incorporated by reference
in this prospectus supplement and the accompanying prospectus.
Overview
We are a clinical-stage biopharmaceutical
company developing cell and gene therapies for life-threatening diseases. Our lead clinical program is EB-101, an autologous, engineered
cell therapy currently in development for recessive dystrophic epidermolysis bullosa (“RDEB”). In November 2022, we announced
positive topline data from the VIITAL™ study evaluating the efficacy, safety and tolerability of EB-101. The VIITAL™ study
met its two co-primary efficacy endpoints demonstrating statistically significant, clinically meaningful improvements in wound healing
and pain reduction in large chronic RDEB wounds. Based on the positive topline results, we intend to submit a Biologics License Application
(“BLA”) for EB-101 to the U.S. Food and Drug Administration (“FDA”) in the third quarter of 2023.
Our development portfolio also features
adeno-associated virus (“AAV”) based gene therapies designed to treat ophthalmic diseases using the novel AIM™ capsid
platform that we have exclusively licensed from the University of North Carolina at Chapel Hill, and internal AAV vector research programs.
We have continued to prepare our current
Good Manufacturing Practices (“cGMP”) commercial facility in Cleveland, Ohio for manufacturing EB-101 drug product to support
our planned BLA filing to the FDA. EB-101 study drug product for all our VIITAL™ study participants has been manufactured at our
Cleveland facility. As part of our commercial planning, we continue to engage with stakeholders across the healthcare system, including
public and private payors, and healthcare providers to better understand market access and potential pricing for EB-101.
Preclinical
Pipeline
Our preclinical
programs are investigating the use of novel AAV capsids in AAV-based therapies for serious genetic eye diseases, including ABO-504 for
Stargardt disease, ABO-503 for X-linked retinoschisis (“XLRS”) and ABO-505 for autosomal dominant optic atrophy (“ADOA”).
In 2022, we evaluated the ability of our gene constructs and capsids to deliver and express the recombinant protein in target eye tissues
and rescue mutant phenotypes in mouse disease models. During the second quarter of 2023, we participated in pre-Investigational New Drug
(“IND”) application meetings with the FDA to gain alignment on IND enabling studies.
Company Information
We were incorporated in 1974. On October
24, 2014, we changed our name to PlasmaTech Biopharmaceuticals, Inc., and on June 19, 2015, we changed our name to Abeona Therapeutics
Inc. to reflect our broader rare disease commitment. Our principal executive office is located at 6555 Carnegie Avenue, 4th
Floor, Cleveland, Ohio 44103, and our telephone number is (646) 813-4701. Our website address is www.abeonatherapeutics.com. We do not
incorporate by reference into this prospectus supplement the information on our website, and you should not consider it as part of this
prospectus supplement.
THE OFFERING
Common stock offered |
|
3,284,407 shares. |
|
|
|
Pre-funded warrants offered |
|
We are also offering, in lieu of common stock, pre-funded warrants to purchase 2,919,140 shares
of our common stock. The purchase price of each pre-funded warrant is equal to the price per share at which the shares of our common
stock are being sold in this offering, minus $0.0001, and the exercise price of each pre-funded warrant is $0.0001 per share. Each
pre-funded warrant is exercisable at any time after the date of execution, subject to an ownership limitation. See “Description
of Pre-Funded Warrants.” This prospectus supplement also relates to the offering of the shares of our common stock issuable
upon exercise of the pre-funded warrants. |
|
|
|
Common stock to be outstanding immediately after this offering |
|
21,213,751 shares, assuming no exercise of any pre-funded warrants offered hereby. Assuming
all of the pre-funded warrants were immediately exercised, there would be 24,132,891 shares of common stock outstanding after
this offering. |
|
|
|
Use of proceeds |
|
We estimate that the net proceeds to us from this offering, after deducting placement agent fees
and paying estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the pre-funded warrants
offered hereby, will be approximately $22.9 million. We expect to use the net proceeds of this offering primarily to fund
preparations for commercialization of our product candidate EB-101, as well as for working capital and general corporate purposes.
See “Use of Proceeds” on page S-7 of this prospectus supplement for a more complete description of the intended use of
proceeds from this offering. |
|
|
|
Risk Factors |
|
Investing in our securities involves significant risks. Please read the information contained in
or incorporated by reference under the heading “Risk Factors” beginning on page S-5 of this prospectus supplement,
and under similar headings in documents incorporated by reference into this prospectus supplement and the accompanying prospectus. |
|
|
|
Nasdaq Capital Market symbol |
|
ABEO |
The number of shares of
our common stock to be outstanding after this offering is based on 17,929,344 shares of our common stock outstanding as of March 31,
2023, which amount excludes:
| ● | 234,697 shares issuable upon the exercise of stock options outstanding
as of March 31, 2023, at a weighted average exercise price of $37.00 per share; |
| ● | 1,680,709 shares of common stock issued under our equity incentive plans during the second quarter of 2023; |
| ● | 149,291 shares of common stock reserved for future issuance under our 2023 equity incentive plan, which
plan became effective as of May 17, 2023; |
| ● | 9,397,879 shares of common stock issuable upon the exercise of warrants outstanding as of March 31, 2023,
at a weighted average exercise price of $5.70 per share, subject to customary adjustments thereunder; |
| ● | 1,891,761 shares of common stock that we issued and sold in the second quarter of 2023 pursuant to our open
market sale agreement with Jefferies LLC; and |
| ● | 2,919,140 shares of common stock issuable upon the exercise of the pre-funded warrants offered hereby. |
Unless otherwise indicated, all information
in this prospectus supplement assumes no exercises of the pre-funded warrants offered and sold in this offering and no exercises of outstanding
options or warrants.
RISK FACTORS
An investment in our securities involves
risks. Before making an investment decision, we urge you to consider carefully the risks described below and in the documents incorporated
by reference in this prospectus supplement and the accompanying prospectus, including those risks identified under Item 1A. “Risk
Factors” and the factors listed under the heading “Forward-Looking Information,” in each case contained in our Annual
Report on Form 10-K for the year ended December 31, 2022, as amended, and our Form 10-Q for the quarter ended March 31, 2023, which are
incorporated by reference in this prospectus and may be amended, supplemented or superseded from time to time by other reports that we
subsequently file with the SEC. Additional risks are incorporated by reference into this prospectus supplement in connection with this
offering. Each of the risks described could result in a decrease in the value of our securities and your investment therein.
Risks Related to our
Common Stock and this Offering
The net proceeds
from this offering will be invested based on our management’s discretion and judgment, and there can be no assurance that such
investments will be successful.
Our management will have broad discretion
over the use of the net proceeds from this offering, you may not agree with how we use the proceeds, and the proceeds may not be invested
successfully. As you will be relying on the discretion and judgment of our management with regard to the use of these net proceeds following
the consummation of this offering, you will not have the opportunity, at the time of your investment decision, to assess whether such
proceeds are being used appropriately. It is possible that such proceeds will be invested in a way that does not yield a favorable, or
any, return for Abeona.
You will experience
immediate and substantial dilution in the book value per share of the common stock you purchase in the offering. In addition, holders
of our common stock may incur dilution due to issuances pursuant to the exercise of outstanding options or warrants.
You will incur immediate
and substantial dilution as a result of this offering. The offering price per share of our common stock offered pursuant to this prospectus
supplement is substantially higher than the net tangible book value per share. Accordingly, at the offering price of $4.03 per
share, purchasers of common stock in this offering will experience immediate dilution of $2.31 per share in as adjusted net tangible
book value of the common stock. In addition, as of March 31, 2023, there were 234,697 shares subject to outstanding options at a weighted
average exercise price of $37.00 per share, and 9,397,879 shares of common stock issuable upon the exercise of outstanding warrants at
a weighted average exercise price of $5.70 per share, subject to customary adjustments thereunder. To the extent that additional shares
of common stock are issued upon exercise of these outstanding options or warrants, you will incur further dilution. Furthermore, if the
pre-funded warrants offered hereby are exercised, you will incur further dilution. See “Dilution” for a more detailed discussion
of the dilution you will incur if you purchase shares of common stock in this offering. We may also acquire or license other technologies
or finance strategic alliances by issuing equity, which may result in additional dilution to our stockholders.
You may experience
future dilution as a result of future equity offerings.
To raise additional capital, we may
in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at
prices that may not be the same as the prices per share in this offering. We may sell shares or other securities in any other offering,
including under our open market sale agreement with Jefferies LLC, at a price per share that is less than the prices per share paid by
investors in this offering, and investors purchasing shares of our common stock or other securities in the future could have rights superior
to existing stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable
into common stock, in future transactions may be higher or lower than the prices per share paid by investors in this offering.
We may require additional
capital funding, the receipt of which may impair the value of our common stock.
Our future capital requirements depend
on many factors, including our research, development, sales and marketing activities. We may need to raise additional capital through
public or private equity or debt offerings or through arrangements with strategic partners or other sources in order to continue to develop
our drug candidates. There can be no assurance that additional capital will be available when needed or on terms satisfactory to us,
if at all. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution
and the new equity securities may have greater rights, preferences or privileges than our existing common stock.
There is no public market for
the pre-funded warrants being offered in this offering.
There is no public trading market for
the pre-funded warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply
to list the pre-funded warrants on any securities exchange or nationally recognized trading system, including the Nasdaq Capital Market.
Without an active market, the liquidity of the pre-funded warrants will be limited.
We may not receive any additional
funds upon the exercise of the pre-funded warrants.
Each pre-funded warrant may be exercised
by way of a cashless exercise, meaning that the holder may not pay a cash purchase price upon exercise, but instead would receive upon
such exercise the net number of shares of our common stock determined according to the formula set forth in the pre-funded warrant. Accordingly,
we may not receive any additional funds upon the exercise of the pre-funded warrants.
Holders of pre-funded warrants
purchased in this offering will have no rights as holders of our common stock with respect to the shares underlying such pre-funded warrants
until such holders exercise their pre-funded warrants and acquire our common stock.
Until holders of pre-funded warrants
acquire shares of our common stock upon exercise of the pre-funded warrants, holders of pre-funded warrants will have no rights with
respect to the shares of our common stock underlying such pre-funded warrants including with respect to dividends and voting rights.
Upon exercise of the pre-funded warrants, the holders will be entitled to exercise the rights of a holder of our common stock only as
to matters for which the record date occurs after the exercise date.
Significant holders or beneficial
holders of our common stock may not be permitted to exercise pre-funded warrants that they hold.
A holder of a pre-funded
warrant will not be entitled to exercise any portion of any pre-funded warrant which, upon giving effect to such exercise, would cause
(i) the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 4.99%
(or, at the election of the holder, 9.99%) of the number of shares of our common stock outstanding immediately after giving effect
to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder (together with its affiliates)
to exceed 4.99% (or, at the election of the holder, 9.99%) of the combined voting power of all of our securities then outstanding
immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded
warrants. As a result, you may not be able to exercise your pre-funded warrants for shares of our common stock at a time when it would
be financially beneficial for you to do so. In such circumstance you could seek to sell your pre-funded warrants to realize value, but
you may be unable to do so in the absence of an established trading market for the pre-funded warrants.
USE OF PROCEEDS
We estimate that the net
proceeds from the sale of the shares and pre-funded warrants offered hereby will be approximately $22.9 million after deducting
placement agent fees and paying estimated offering expenses payable by us. We will receive nominal proceeds, if any, upon exercise of
the pre-funded warrants.
We intend to use the net proceeds from
this offering primarily to fund preparations for commercialization of our product candidate EB-101, as well as for working capital and
general corporate purposes. The amounts and timing of our use of the net proceeds from the sale of securities in this offering will depend
on a number of factors, such as regulatory approvals, commercial infrastructure expansion, the timing and progress of our pre-clinical
product candidates and our development efforts, technological advances and the competitive environment for our product candidates.
As of the date of this
prospectus supplement, we cannot specify with certainty all of the particular uses for the net proceeds to us from this offering. Accordingly,
our management will have broad discretion in the timing and application of these proceeds. Pending application of the net proceeds as
described above, we may invest the net proceeds of this offering in a variety of capital preservation investments, including but not
limited to short-term, interest-bearing investment grade government securities, money market accounts, certificates of deposit
and direct or guaranteed obligations of the U.S. government.
DILUTION
If you invest in our common
stock, your ownership interest will be diluted to the extent of the difference between the price per share you pay in this offering and
the net tangible book value per share of our common stock immediately after this offering. The net tangible book value of our common
stock as of March 31, 2023, was approximately $13.6 million, or approximately $0.76 per share of common stock based upon
17,929,344 shares outstanding. Net tangible book value per share is equal to our total tangible assets, less our total liabilities, divided
by the total number of shares outstanding as of March 31, 2023.
After giving effect to
the sale of 3,284,407 shares of common stock at an offering price of $4.03 per share and pre-funded warrants to
purchase 2,919,140 shares of common stock at the offering price of $4.0299 per pre-funded warrant (which equals the offering
price per share of our common stock less the $0.0001 per share exercise price of each such pre-funded warrant) (and excluding shares
of our common stock issued and any proceeds received upon exercise of the pre-funded warrants or any resulting accounting associated
with the pre-funded warrants), our as adjusted net tangible book value as of March 31, 2023, would have been approximately $36.6
million, or $1.72 per share of common stock. This represents an immediate increase in net tangible book value of $0.96
per share to our existing stockholders and an immediate dilution in net tangible book value of $2.31 per share to new investors
in this offering.
The following table illustrates this
per share dilution:
Offering price per share | |
$ | 4.03 | |
Net tangible book value per share as of March 31, 2023 | |
| 0.76 | |
Increase per share attributable to new investors | |
| 0.96 | |
As adjusted net tangible book value per share as of March 31, 2023, after giving
effect to this offering(1) | |
| 1.72 | |
Dilution per share to new investors purchasing shares in this offering | |
$ | 2.31 | |
(1) | As adjusted net tangible book value per share
and dilution per share take into account the net proceeds from the sale of the pre-funded warrants
but not the shares of common stock to be issued upon exercise of the pre-funded warrants. |
If holders of pre-funded
warrants exercise the pre-funded warrants in full, the as adjusted net tangible book value per share of common stock after giving effect
to this offering would be $1.51 per share, and the dilution in net tangible book value per share to investors purchasing common
stock in this offering would be $2.52 per share.
The number of shares of
our common stock to be outstanding after this offering is based on 17,929,344 shares of our common stock outstanding as of March 31,
2023, which amount excludes:
| ● | 234,697 shares issuable upon the
exercise of stock options outstanding as of March 31, 2023, at a weighted average exercise
price of $37.00 per share; |
| ● | 1,680,709 shares of common stock issued under our equity incentive plans during
the second quarter of 2023; |
| ● | 149,291 shares of common stock reserved for future issuance under our 2023 equity
incentive plan, which plan became effective as of May 17, 2023; |
| ● | 9,397,879 shares of common stock issuable upon the exercise of warrants outstanding
as of March 31, 2023, at a weighted average exercise price of $5.70 per share, subject to customary adjustments
thereunder; |
| ● | 1,891,761 shares of common stock that we issued and sold in the second quarter
of 2023 pursuant to our open market sale agreement with Jefferies LLC; and |
| ● | 2,919,140 shares of common stock issuable upon the exercise of the pre-funded
warrants offered hereby. |
DESCRIPTION OF PRE-FUNDED WARRANTS
The following is a brief summary of
certain terms and conditions of the pre-funded warrants being offered by us. The following description is subject in all respects to
the provisions contained in the pre-funded warrants.
Form
The pre-funded warrants will be issued
as individual warrant agreements to each individual purchaser of a pre-funded warrant. The form of pre-funded warrant will be filed as
an exhibit to a Current Report on Form 8-K that we will file with the SEC.
Term
The pre-funded warrants do not expire.
Exercisability
The pre-funded warrants are exercisable
at any time after their original issuance. The pre-funded warrants will be exercisable, at the option of each holder, in whole or in
part, by delivering to us a duly executed exercise notice and by payment in full of the exercise price in immediately available funds
for the number of shares of our common stock purchased upon such exercise. As an alternative to payment of the exercise price in immediately
available funds, the holder may elect to exercise the pre-funded warrant through a cashless exercise, in which case the holder would
receive upon such exercise the net number of shares of our common stock determined according to the formula set forth in the pre-funded
warrant. No fractional shares of our common stock will be issued in connection with the exercise of a pre-funded warrant. In lieu of
fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the last closing trading price
of our common stock on the exercise date.
Exercise Limitations
Under the pre-funded warrants,
we may not effect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded
warrant, which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of our common stock beneficially
owned by the holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99%) of the number of
shares of our common stock outstanding immediately after giving effect to the exercise, or (i) the combined voting power of our securities
beneficially owned by the holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99%) of
the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage
ownership is determined in accordance with the terms of the pre-funded warrants.
Exercise Price
The exercise price per whole share of
our common stock issuable upon the exercise of the pre-funded warrants is $0.0001 per share of our common stock. The exercise price of
the pre-funded warrants and the number of shares of our common stock issuable upon exercise of the pre-funded warrants are subject to
appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications
or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our
stockholders.
Transferability
Subject to applicable laws, the pre-funded
warrants may be offered for sale, sold, transferred or assigned without our consent. The pre-funded warrants will be held in definitive
form by the purchasers. The ownership of the pre-funded warrants and any transfers of the pre-funded warrants will be registered in a
warrant register maintained by us or our transfer agent.
Exchange Listing
We do not plan on applying to list the
pre-funded warrants on The Nasdaq Capital Market, any other national securities exchange or any other nationally recognized trading system.
Fundamental Transactions
In the event of a fundamental
transaction, as described in the pre-funded warrants and generally including any reorganization, recapitalization or reclassification
of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation
or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming
the beneficial owner of 50% of the voting power represented by our outstanding common stock, upon consummation of such a fundamental
transaction, the holders of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the kind and
amount of securities, cash or other property that the holders would have received had they exercised the pre-funded warrants immediately
prior to such fundamental transaction without regard to any limitations on exercise contained in the pre-funded warrants, and any
additional consideration receivable as a result of such fundamental transaction.
No Rights as a Stockholder
Except by virtue of such holder’s
ownership of shares of our common stock, the holder of a pre-funded warrant does not have the rights or privileges of a holder of our
common stock, including any voting rights or the rights to receive dividends, until the holder exercises the pre-funded warrant.
PLAN OF DISTRIBUTION
We have engaged Cantor
Fitzgerald & Co. to act as our sole lead-placement agent and A.G.P./Alliance Global Partners as our co-placement agent to solicit
offers to purchase the securities offered by this prospectus supplement and the accompanying prospectus in a registered direct offering
to a limited number of purchasers pursuant to this prospectus supplement and the accompanying prospectus. The placement agents are
not purchasing or selling any such securities, nor are they required to arrange for the purchase and sale of any specific
number or dollar amount of such securities. Therefore, we may not sell all of the securities being offered. The terms of this offering
were subject to market conditions and negotiations between us and the prospective investors. We have entered into a securities purchase
agreement directly with the investors who have agreed to purchase our securities in this offering. We will only sell securities in this
offering to such investors.
Delivery of the securities
offered hereby is expected to take place on or about July 6, 2023, subject to satisfaction of customary closing conditions.
Fees and Expenses
We have agreed to pay the
placement agents a cash fee equal to 7% of the aggregate gross proceeds from the offering. The following table shows the per share
and total cash fees we will pay to the placement agents in connection with the sale of our securities offered pursuant to this
prospectus supplement and the accompanying prospectus, assuming the purchase of all of the securities offered hereby.
| |
Per Share | | |
Per Pre-Funded Warrant | | |
Total | |
Offering price | |
$ | 4.0300 | | |
$ | 4.0299 | | |
$ | 25,000,002 | |
Placement agent fees(1) | |
$ | 0.2821 | | |
$ | 0.2821 | | |
$ | 1,750,000 | |
Proceeds to Abeona Therapeutics Inc., before expenses(2) | |
$ | 3.7479 | | |
$ | 3.7478 | | |
$ | 23,250,002 | |
(1) | Includes a cash fee of 7% of the aggregate gross
proceeds of this offering. |
(2) | The above summary of offering proceeds does not give effect to any
proceeds from the exercise of the pre-funded warrants being delivered in this offering. |
We estimate expenses payable
by us in connection with this offering, other than the placement agent fees referred to above, will be approximately $300,000.
We have also agreed to reimburse the placement agents for up to $50,000 (which may be increased with our written consent)
for certain fees and expenses incurred in connection with this offering, including its counsel fees.
In addition, we have granted
Cantor Fitzgerald & Co. the right to participate in distributions of certain future financing transactions by the Company, including
private placements, subject to certain limitations. In accordance with FINRA Rule 5110 this right constitutes 1% in underwriting compensation
for this offering and will have a duration of less than three years in accordance with FINRA Rule 5110(g)(6)(A).
Listing
Our common stock is listed
on the Nasdaq Capital Market under the trading symbol “ABEO.” We do not intend to list the pre-funded warrants on the Nasdaq
Capital Market, any other nationally recognized securities exchange or any other nationally recognized trading system.
No Sales of Similar
Securities
We and our officers and
directors have agreed, subject to specified exceptions, not to directly or indirectly:
| ● | sell, offer, contract or grant any
option to sell (including any short sale), pledge, transfer, establish an open “put
equivalent position” within the meaning of Rule 16a-1(h) under the Securities Exchange
Act of 1934, as amended (“Exchange Act”); |
| ● | otherwise dispose of any shares of
common stock, options or warrants to acquire shares of common stock, or securities exchangeable
for or exercisable for or convertible into shares of common stock currently or hereafter
owned either of record or beneficially; or |
| ● | publicly announce an intention to
do any of the foregoing. |
The restriction terminates,
with respect to such officers and directors, after the close of trading of the common stock on and including the 60th day
after the date of this prospectus supplement and, with respect to us, after the close of trading of the common stock on and including
the 120th day after the date of this prospectus supplement. There are no existing agreements between us and any of our officers
and directors who have executed a lock-up agreement, providing consent to the sale of shares prior to the expiration of the lock-up period.
The restrictions described above will not apply to shares delivered as a result of the exercise of the pre-funded warrants.
Other Activities and
Relationships
The placement agents
and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities
trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging,
financing and brokerage activities. The placement agents and certain of their affiliates have, from time to time, performed,
and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for
which they received or will receive customary fees and expenses.
In the ordinary course
of their various business activities, the placement agents and certain of their affiliates may make or hold a broad array
of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including
bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve
securities and/or instruments issued by us and our affiliates. If the placement agents or their affiliates have a lending
relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies. The
placement agents and their affiliates may hedge such exposure by entering into transactions that consist of either the
purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including
potentially the common stock offered hereby. Any such short positions could adversely affect future trading prices of the common stock
offered hereby. The placement agents and certain of their affiliates may also communicate independent investment recommendations,
market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may
at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.
LEGAL MATTERS
The validity of the common
stock and pre-funded warrants being offered hereby will be passed upon for us by Willkie Farr & Gallagher LLP, New York, New York.
Covington & Burling LLP, New York, New York, is counsel to the placement agents in connection with this offering.
EXPERTS
The consolidated financial statements,
incorporated by reference from the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, have been
audited by Whitley Penn LLP, an independent registered public accounting firm, as stated in their report filed with the Company’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which is also incorporated herein by reference. Such financial
statements have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and
auditing.
WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION
BY REFERENCE
We file annual, quarterly and current
reports, proxy statements and other information with the SEC. The SEC maintains a website at www.sec.gov that contains reports, statements
and other information about issuers, such as us, who file electronically with the SEC. We maintain a website at www.abeonatherapeutics.com.
However, the information on our website is not incorporated by reference into this prospectus supplement or the accompanying prospectus
and you should not consider it a part of this prospectus supplement or the accompanying prospectus.
The SEC allows us to “incorporate
by reference” into this prospectus supplement the information in other documents that we file with it. This means that we can disclose
important information to you by referring you to those documents. The information incorporated by reference is considered to be a part
of this prospectus supplement, and information in documents that we file later with the SEC will automatically update and supersede information
contained in documents filed earlier with the SEC or contained in this prospectus supplement. We incorporate by reference into this prospectus
supplement the documents listed below; provided, however, that we are not incorporating, in each case, any documents or information
deemed to have been furnished and not filed in accordance with SEC rules:
| ● | our Annual Report on Form 10-K for the year ended December 31,
2022 (filed on March 29, 2023), as amended by Amendment No. 1 on Form 10-K/A filed on April
10, 2023; |
| ● | the portions of our definitive proxy statement on Schedule 14A
filed on April 13, 2023, that are incorporated by reference into Part III of our Annual Report
on Form 10-K for the year ended December 31, 2022; |
| ● | our Quarterly Report on Form 10-Q for the quarterly period ended
March 31, 2023 (filed on May 11, 2023); |
| ● | our Current Reports on Form 8-K filed on April 11, 2023, and
May 17, 2023; and |
| ● | the description of our common stock, par value $0.01 per share
contained in our Registration Statement on Form 8-A, dated and filed with the SEC on November
4, 2014, as updated by Exhibit 4.4 to our Form 10-K for the fiscal year ended December 31,
2019, and including any amendments or reports filed with the SEC for the purpose of updating
such description. |
All reports and other documents we subsequently
file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this offering, including all such
documents we may file with the SEC after the date of the initial registration statement, but excluding any information furnished to,
rather than filed with, the SEC, will also be incorporated by reference into this prospectus supplement and deemed to be part of this
prospectus supplement from the date of the filing of such reports and documents.
You may obtain a copy of any or all
of the documents referred to above which may have been or may be incorporated by reference into this prospectus supplement, except for
exhibits to those documents (unless the exhibits are specifically incorporated by reference into those documents), at no cost to you
by writing or telephoning us at the following address and telephone number: Abeona Therapeutics Inc., Attn: Investor Relations, 6555
Carnegie Avenue, 4th Floor, Cleveland, Ohio 44103, telephone (646) 813-4701.
PROSPECTUS
$250,000,000
ABEONA
THERAPEUTICS INC.
Common
Stock
Preferred
Stock
Warrants
Debt
Securities
This
prospectus will allow us to issue, from time to time at prices and on terms to be determined at or prior to the time of the offering,
up to $250,000,000 of any combination of the securities described in this prospectus. We may also offer common stock or preferred stock
upon conversion of or exchange for the debt securities or common stock, preferred stock or debt securities upon the exercise of warrants.
This
prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will
provide you with the specific terms of any offering in one or more supplements to this prospectus. We may also authorize one or more
free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplements and any related free writing
prospectus will also describe the specific manner in which these securities will be offered and may also supplement, update or amend
information contained in this document. You should read this prospectus, any prospectus supplement, and any related free writing prospectus,
as well as any documents incorporated by reference into this prospectus or any prospectus supplement, carefully before you invest.
Our
securities may be sold directly by us to you, through agents designated from time to time or to or through underwriters or dealers. For
additional information on the methods of sale, you should refer to the section entitled “Plan of Distribution” in this prospectus
and in the applicable prospectus supplement. If any underwriters or agents are involved in the sale of our securities with respect to
which this prospectus is being delivered, the names of such underwriters or agents and any applicable fees, commissions or discounts
and over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds
that we expect to receive from such sale will also be set forth in a prospectus supplement.
Our
common stock is listed on The Nasdaq Capital Market (“Nasdaq”), under the symbol “ABEO.” On June 4, 2021, the
last reported sale price of our common stock on Nasdaq was $1.69 per share.
Investing
in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully
the risks that we have described on page 4 of this prospectus under the caption “Risk Factors.” We may include specific risk
factors in supplements to this prospectus and any related free writing prospectus under the caption “Risk Factors.” This
prospectus may not be used to sell our securities unless accompanied by a prospectus supplement.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The
date of this prospectus is October 22, 2021.
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
This
prospectus is part of a “shelf” registration statement. Under this shelf registration process, we may sell, at any time and
from time to time, in one or more offerings, any combination of the securities described in this prospectus. The exhibits to our Registration
Statement contain the full text of certain contracts and other important documents we have summarized in this prospectus. Since these
summaries may not contain all the information that you may find important in deciding whether to purchase the securities we offer, you
should review the full text of these documents. The Registration Statement and the exhibits can be obtained from the Securities and Exchange
Commission (“SEC”) as indicated under the heading “Where You Can Find More Information; Incorporation By Reference.”
This
prospectus only provides you with a general description of the securities we may offer. Each time we sell securities, we will provide
a prospectus supplement that contains specific information about the terms of those securities and the terms of that offering. The prospectus
supplement may also add, update, or change information contained in this prospectus. You should read both this prospectus and any prospectus
supplement together with the additional information described below under the heading “Where You Can Find More Information; Incorporation
By Reference.”
We
have not authorized any dealer, agent, or other person to give any information or to make any representation other than those contained
or incorporated by reference into this prospectus and any accompanying prospectus supplement. You must not rely upon any information
or representation not contained or incorporated by reference into this prospectus or an accompanying prospectus supplement. This prospectus
and the accompanying prospectus supplement, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities
other than the registered securities to which they relate, nor do this prospectus and the accompanying prospectus supplement, if any,
constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful
to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus and
any accompanying prospectus supplement is accurate on any date subsequent to the date set forth on the front of the document or that
any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference,
even though this prospectus and any accompanying prospectus supplement is delivered or securities are sold on a later date.
References
in this prospectus to the terms “the Company,” “Abeona,” “we,” “our” and “us”
or other similar terms mean Abeona Therapeutics Inc., unless we state otherwise or the context indicates otherwise.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus, any prospectus supplement, and the other documents we have filed with the SEC that are incorporated herein by reference contain
forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts,
regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, objectives
of management or other financial items are forward-looking statements. The words “anticipate,” “believe,” “estimate,”
“expect,” “seek,” “intend,” “may,” “plan,” “predict,” “project,”
“will,” “would” and similar expressions are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
We
may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place
undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations
disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this
prospectus, particularly as set forth and incorporated by reference into the “Risk Factors” section below, that we believe
could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements
do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, collaborations, or investments
we may make.
You
should read this prospectus, any supplements to this prospectus and the documents that we incorporate by reference into this prospectus
completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume
any obligation to update any forward-looking statements, except as otherwise required by law. We advise you, however, to consult any
further disclosures we make on related subjects in our future annual reports on Form 10-K, quarterly reports on Form 10-Q and current
reports on Form 8-K we file with or furnish to the SEC.
THE
COMPANY
Overview
Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic
diseases. Our lead clinical programs consist of (i) EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis
bullosa (“RDEB”), (ii) ABO-102, an adeno-associated virus (“AAV”)-based gene therapy for Sanfilippo syndrome
type A (“MPS IIIA”), and (iii) ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B (“MPS IIIB”).
We continue to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases, next-generation AAV-based
gene therapies using our own novel capsids and capsids from the AIM™ capsid library that we have exclusively licensed from the
University of North Carolina at Chapel Hill, and internal AAV vector research programs. A number of our product candidates are eligible
for orphan drug designation, breakthrough therapy designation, or other expedited review processes in the U.S., Europe, Japan, or other
world markets. Our pipeline includes three programs in clinical development—EB-101, ABO-101 and ABO-102—for which we hold
several U.S. and European Union (“EU”) regulatory designations, and a pipeline of additional earlier stage programs.
Our
Mission and Strategy
Abeona
is at the forefront of gene and cell therapy research and development. We are a fully-integrated company featuring therapies in clinical
development, in-house manufacturing facilities, a robust pipeline, and scientific and clinical leadership. We see our mission as working
to create, develop, manufacture, and deliver gene and cell therapies for people impacted by serious diseases. We partner with leading
academic researchers, patient advocacy organizations and caregivers to develop therapies that address the underlying cause of a broad
spectrum of rare genetic diseases for which no effective treatment options exist today.
Since
our last fiscal year, we have continued to make progress toward fulfilling our goal of harnessing the promise of genetic medicine to
transform the lives of people impacted by serious diseases and redefining the standard of care through gene and cell therapies. Our strategy
to achieve this goal consists of:
Advancing
Our Clinical Gene and Cell Therapy Programs and Research and Development with a Focus on Rare and Orphan Diseases.
We
have three programs in clinical development—EB-101, ABO-101 and ABO-102—and a pipeline of additional earlier stage programs.
Through our gene and cell therapy research and development expertise, we believe we are positioned to introduce efficacious and safe
therapeutics to transform the standard of care in devastating diseases and establish our leadership position in the field.
Applying
Novel Next-Generation AIM™ Capsid Technology to Develop New In-Vivo Gene Therapies.
We
are researching and developing next-generation AAV-based gene therapy using our own novel capsids and capsids from the AIM™ capsid
library. We plan to continue to develop AAV capsids capable of improved tissue targeting for various indications and potentially evading
immunity to wildtype AAV vectors.
Establishing
Leadership Position in Commercial-Scale Gene and Cell Therapy Manufacturing.
We
established current Good Manufacturing Practice (“cGMP”), clinical-scale manufacturing capabilities for gene-corrected cell
therapy and AAV-based gene therapies in our state-of-the-art Cleveland facility. We believe that our platform provides us with distinct
advantages, including flexibility, scale, reliability, and the potential for reduced development risk, reduced cost, and faster times
to market. We have focused on establishing internal Chemistry, Manufacturing and Controls (“CMC”) capabilities that drive
value for our organization through process development, assay development and manufacturing. We have also deployed robust quality systems
governing all aspects of product lifecycle from preclinical through commercial stage.
Establishing
Additional Gene and Cell Therapy Franchises and Adjacencies through In-Licensing and Strategic Partnerships.
We
seek to be the partner of choice in gene therapy treatment and have closely collaborated with leading academic institutions, key opinion
leaders, patient foundations, and industry partners to generate novel intellectual property, accelerate research and development, and
understand the needs of patients and their families.
Maintaining
and Growing Our IP Portfolio.
We
strive to have a leading intellectual property portfolio. To that end, we seek patent rights for various aspects of our programs, including
vector engineering and construct design, our production process, and all features of our clinical products including composition of matter
and method of administration and delivery. We expect to continue to expand our intellectual property portfolio by aggressively seeking
patent rights for promising aspects of our product engine and product candidates.
Company
Information
We
were incorporated in 1974. On October 24, 2014, we changed our name to PlasmaTech Biopharmaceuticals, Inc., and on June 19, 2015, we
changed our name to Abeona Therapeutics Inc. to reflect our broader rare disease commitment. Our principal executive office is located
at 1330 Avenue of the Americas, 33rd Floor, New York, NY 10019 and our telephone number is (646) 813-4701. Our website is www.abeonatherapeutics.com.
We do not incorporate by reference into this prospectus the information on our website, and you should not consider it as part of this
prospectus supplement.
RISK
FACTORS
An
investment in our securities involves risks and uncertainties. Before making an investment decision, you should carefully consider these
risks as well as other information we include or incorporate by reference in this prospectus. In particular, you should carefully consider
the information under the heading “Risk Factors,” as well as the factors listed under the heading “ Forward-Looking
Statements,” in each case contained in our Annual Report on Form 10-K for our most recent fiscal year, in any Quarterly Reports
on Form 10-Q that have been filed since our most recent Annual Report on Form 10-K, and in any other documents that we file (not furnish)
with the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), each of which is incorporated by
reference in this prospectus. Any of the risks described could significantly and negatively affect our business, financial condition,
results of operations, cash flows and prospects and the trading price of our securities. You could lose all or part of your investment.
USE
OF PROCEEDS
Unless
otherwise specified in a prospectus supplement accompanying this prospectus, the net proceeds from the sale of the securities to which
this prospectus relates will be used to fund continued clinical development of pipeline products, as well as for working capital and
general corporate purposes. General corporate purposes may include repayment of debt, acquisitions, additions to working capital, capital
expenditures, research and development and investments in our subsidiaries. Net proceeds may be temporarily invested prior to use.
PLAN
OF DISTRIBUTION
We
may sell the offered securities in any of the ways described below or in any combination or any other way set forth in an applicable
prospectus supplement from time to time:
| ● | to
or through underwriters or dealers; |
| ● | through
one or more agents; or |
| ● | directly
to purchasers or to a single purchaser. |
The
distribution of the securities may be effected from time to time in one or more transactions:
| ● | at
a fixed price, or prices, which may be changed from time to time; |
| ● | at
market prices prevailing at the time of sale; |
| ● | at
prices related to such prevailing market prices; or |
Each
prospectus supplement will describe the method of distribution of the securities and any applicable restrictions.
The
prospectus supplement with respect to the securities of a particular series will describe the terms of the offering of the securities,
including the following:
| ● | the
name or names of any underwriters, dealers or agents and the amounts of securities underwritten
or purchased by each of them; |
| ● | the
public offering price of the securities and the proceeds to us and any discounts, commissions
or concessions allowed or reallowed or paid to dealers; and |
| ● | any
securities exchanges on which the securities may be listed. |
Any
offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time.
Only
the agents or underwriters named in each prospectus supplement are agents or underwriters in connection with the securities being offered
thereby.
We
may authorize underwriters, dealers or other persons acting as our agents to solicit offers by certain institutions to purchase securities
from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in each applicable prospectus supplement.
Each contract will be for an amount not less than, and the aggregate amount of securities sold pursuant to such contracts shall not be
less nor more than, the respective amounts stated in each applicable prospectus supplement. Institutions with whom the contracts, when
authorized, may be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational and
charitable institutions, and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts will be
subject only to those conditions set forth in each applicable prospectus supplement, and each prospectus supplement will set forth any
commissions we pay for solicitation of these contracts.
Agents,
underwriters and other third parties described above may be entitled to indemnification by us against certain civil liabilities, including
liabilities under the Securities Act of 1933, as amended (the “Securities Act”), or to contribution from us with respect
to payments which the agents, underwriters or other third parties may be required to make in respect thereof. Agents, underwriters and
such other third parties may be customers of, engage in transactions with, or perform services for us in the ordinary course of business.
One
or more firms, referred to as “remarketing firms,” may also offer or sell the securities, if a prospectus supplement so indicates,
in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for their own accounts or
as our agents. These remarketing firms will offer or sell the securities in accordance with the terms of the securities. Each prospectus
supplement will identify and describe any remarketing firm and the terms of its agreement, if any, with us and will describe the remarketing
firm’s compensation. Remarketing firms may be deemed to be underwriters in connection with the securities they remarket. Remarketing
firms may be entitled under agreements that may be entered into with us to indemnification by us against certain civil liabilities, including
liabilities under the Securities Act, and may be customers of, engage in transactions with or perform services for us in the ordinary
course of business.
Certain
underwriters may use this prospectus and any accompanying prospectus supplement for offers and sales related to market-making transactions
in the securities. These underwriters may act as principal or agent in these transactions, and the sales will be made at prices related
to prevailing market prices at the time of sale.
The
securities we offer may be new issues of securities and may have no established trading market. The securities may or may not be listed
on a securities exchange. Underwriters may make a market in these securities, but will not be obligated to do so and may discontinue
any market making at any time without notice. We can make no assurance as to the liquidity of, or the existence of trading markets for,
any of the securities.
Certain
persons participating in an offering may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids
in accordance with rules and regulations under the Exchange Act. Overallotment involves sales in excess of the offering size, which create
a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed
a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed
to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally
sold by the dealer are purchased in a short covering transaction to cover short positions. Those activities may cause the price of the
securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time.
We
also may sell any of the securities through agents designated by us from time to time. We will name any agent involved in the offer or
sale of these securities and will list commissions payable by us to these agents in the applicable prospectus supplement. These agents
will be acting on a best efforts basis to solicit purchases for the period of its appointment, unless stated otherwise in the applicable
prospectuses.
We
may sell any of the securities directly to purchasers. In this case, we will not engage underwriters or agents in the offer and sale
of these securities.
We
may engage in sales deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act, including
sales made directly on or through Nasdaq, the existing trading market for our common stock, sales made to or through a market maker other
than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to
such prevailing market prices and/or any other method permitted by law. The terms of such “at the market offerings” will
be set forth in the applicable prospectus supplement. We may engage an agent to act as a sales agent in such “at the market offerings”
on a best efforts basis using commercially reasonable efforts consistent with normal trading and sales practices, on mutually agreed
terms between such agent and us. We will name any agent involved in such “at the market offerings” of securities and will
list commissions payable by us to these agents in the applicable prospectus supplement.
In
addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties
in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the
third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions.
If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related
open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings
of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in
the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial
institution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement.
Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection
with a concurrent offering of other securities.
The
specific terms of any lock-up provisions in respect of any given offering will be described in the applicable prospectus supplement.
In
compliance with the guidelines of the Financial Industry Regulatory Authority, Inc. (“FINRA”), the maximum consideration
or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate proceeds of the offering.
The
underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for
which they receive compensation.
GENERAL
DESCRIPTION OF SECURITIES THAT WE MAY SELL
We
may offer and sell, at any time and from time to time:
| ● | Shares
of our common stock; |
| ● | Shares
of our preferred stock; |
| ● | Warrants
to purchase shares of our common stock, preferred stock and/or debt securities; |
| ● | Debt
securities consisting of debentures, notes or other evidences of indebtedness; or |
| ● | Any
combination of these securities. |
The
terms of any securities we offer will be determined at the time of sale. We may issue debt securities that are exchangeable for or convertible
into common stock or any of the other securities that may be sold under this prospectus. When particular securities are offered, a supplement
to this prospectus will be filed with the SEC, which will describe the terms of the offering and sale of the offered securities.
DESCRIPTION
OF OUR COMMON STOCK
Our
authorized capital stock consists of 200,000,000 shares of common stock, $0.01 par value per share, and 2,000,000 shares of preferred
stock, $0.01 par value per share, which may be issued in one or more series. The following summary of the terms of our common stock is
subject to and qualified in its entirety by reference to our restated certificate of incorporation (the “Certificate of Incorporation”)
and amended and restated bylaws (the “Bylaws”). Please refer to “Where You Can Find More Information; Incorporation
By Reference” below for directions on obtaining these documents.
As
of June 4, 2021, we had 99,892,667 shares of common stock outstanding and no shares of preferred stock outstanding.
General
Holders
of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and have the right
to vote cumulatively for the election of directors. This means that in the voting at our annual meeting, each stockholder or his proxy
may multiply the number of his shares by the number of directors to be elected, then cast the resulting total number of votes for a single
nominee, or distribute such votes on the ballot among the nominees as desired. Holders of our common stock are entitled to receive ratably
such dividends, if any, as may be declared by our Board of Directors (the “Board”) out of funds legally available therefor,
subject to any preferential dividend rights for our outstanding preferred stock.
Upon
our liquidation, dissolution, or winding up, the holders of our common stock are entitled to receive ratably our net assets available
after the payment of all debts and other liabilities and subject to the prior rights of any of our outstanding preferred stock. Holders
of our common stock have no preemptive, subscription, redemption, or conversion rights. The rights, preferences, and privileges of holders
of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred
stock which we may designate and issue in the future.
Our
common stockholders may not receive any assets or funds until our creditors have been paid in full and the preferential or participating
rights of our preferred stockholders have been satisfied. If we participate in a corporate merger, consolidation, purchase or acquisition
of property or stock, or other reorganization, any payments or shares of stock allocated to our common stockholders will be distributed
pro rata to holders of our common stock on a per share basis. If we redeem, repurchase, or otherwise acquire for payment any shares of
our common stock, we will treat each share of common stock identically.
We
may issue additional shares of our common stock, if authorized by the Board, without the common stockholders’ approval, unless
required by Delaware law or a stock exchange on which our securities are traded. If we receive the appropriate payment, shares of our
common stock that we issue will be fully paid and nonassessable.
Anti-Takeover
Provisions
We
are subject to the provisions of Section 203 of the General Corporation Law of Delaware (“DGCL”). Section 203 prohibits certain
publicly held Delaware corporations from engaging in a “business combination” with an “interested stockholder,”
for a period of three years after the date of the transaction in which the person became an “interested stockholder,” unless
the business combination is approved in a prescribed manner. A “business combination” includes mergers, asset sales and other
transactions resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an “interested stockholder”
is a person or entity who, together with affiliates and associates, owns (or within the preceding three years, did own) 15% or more of
the corporation’s voting stock. The statute contains provisions enabling a corporation to avoid the statute’s restrictions
if the stockholders holding a majority of the corporation’s voting stock approve the transaction. Moreover, our Certificate of
Incorporation provides that our directors shall be divided into three classes, with the terms of each class to expire in different years.
In
addition, our Certificate of Incorporation, in order to combat “greenmail,” provides in general that any direct or indirect
purchase by us of any of our voting stock or rights to acquire voting stock known to be beneficially owned by any person or group which
holds more than five percent of a class of our voting stock and which has owned the securities being purchased for less than two years
must be approved by the affirmative vote of at least two-thirds of the votes entitled to be cast by the holders of voting stock, subject
to certain exceptions. The prohibition of “greenmail” may tend to discourage or foreclose certain acquisitions of
our securities which might temporarily increase the price of our securities. Discouraging the acquisition of a large block of our securities
by an outside party may also have a potential negative effect on takeovers. Parties seeking control of us through large acquisitions
of our securities will not be able to resort to “greenmail” should their bid fail, thus making such a bid less attractive
to persons seeking to initiate a takeover effort.
Elimination
of Monetary Liability for Officers and Directors
Our
Certificate of Incorporation incorporates certain provisions permitted under DGCL relating to the liability of directors. The provisions
eliminate a director’s liability for monetary damages for a breach of fiduciary duty, including gross negligence, except in circumstances
involving certain wrongful acts, such as the breach of director’s duty of loyalty or acts or omissions involving intentional misconduct
or a knowing violation of law. These provisions do not eliminate a director’s duty of care. Moreover, these provisions do not apply
to claims against a director for certain violations of law, including knowing violations of federal securities law. Our Certificate of
Incorporation also contains provisions to indemnify the directors, officers, employees, or other agents to the fullest extent permitted
by DGCL. We believe that these provisions will assist us in attracting and retaining qualified individuals to serve as directors.
Our
Certificate of Incorporation also contains provisions to indemnify the directors, officers, employees, or other agents to the fullest
extent permitted by DGCL. These provisions may have the practical effect in certain cases of eliminating the ability of stockholders
to collect monetary damages from directors. We believe that these provisions will assist us in attracting or retaining qualified individuals
to serve as our directors.
The
Nasdaq Capital Market
Our
common stock is listed on Nasdaq under the symbol “ABEO.”
Transfer
Agent and Registrar
The
transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, New York, New York.
DESCRIPTION
OF OUR PREFERRED STOCK
The
Board may, without further action by our stockholders, from time to time, direct the issuance of shares of preferred stock in series
and may, at the time of issuance, determine the rights, preferences, and limitations of each series, including voting rights, dividend
rights and redemption and liquidation preferences. Satisfaction of any dividend preferences of outstanding shares of our preferred stock
would reduce the amount of funds available for the payment of dividends on shares of our common stock. Holders of shares of our preferred
stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up of our Company before
any payment is made to the holders of shares of our common stock. In some circumstances, the issuance of shares of preferred stock may
render more difficult or tend to discourage a merger, tender offer or proxy contest, the assumption of control by a holder of a large
block of our securities or the removal of incumbent management. Upon the affirmative vote of the Board, without stockholder approval,
we may issue shares of preferred stock with voting and conversion rights which could adversely affect the holders of shares of our common
stock.
If
we offer a specific class or series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the
prospectus supplement for such offering and will file a copy of the certificate establishing the terms of the preferred stock with the
SEC. To the extent required, this description will include:
| ● | the
title and stated value; |
| ● | the
number of shares offered, the liquidation preference per share and the purchase price; |
| ● | the
dividend rate(s), period(s) and/or payment date(s) or method(s) of calculation for such dividends; |
| ● | whether
dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends
will accumulate; |
| ● | the
procedures for any auction and remarketing, if any; |
| ● | the
provisions for a sinking fund, if any; |
| ● | the
provisions for redemption, if applicable; |
| ● | any
listing of the preferred stock on any securities exchange or market; |
| ● | whether
the preferred stock will be convertible into our common stock, and, if applicable, the conversion
price (or how it will be calculated), the conversion period and any other terms of conversion
(including any anti-dilution provisions, if any); |
| ● | whether
the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange
price (or how it will be calculated), the exchange period and any other terms of exchange
(including any anti-dilution provisions, if any); |
| ● | voting
rights, if any, of the preferred stock; |
| ● | a
discussion of any material U.S. federal income tax considerations applicable to the preferred
stock; |
| ● | the
relative ranking and preferences of the preferred stock as to dividend rights and rights
upon liquidation, dissolution or winding up of the affairs of the Company; |
| ● | any
material limitations on issuance of any class or series of preferred stock ranking senior
to or on parity with the series of preferred stock as to dividend rights and rights upon
liquidation, dissolution or winding up of the Company; and |
| ● | any
other affirmative, negative, or other covenants or contractual rights which might be attendant
with the specific class or series of preferred stock. |
The
preferred stock offered by this prospectus, when issued, will not have, or be subject to, any preemptive or similar rights.
Transfer
Agent and Registrar
The
transfer agent and registrar for any series or class of preferred stock will be set forth in each applicable prospectus supplement.
DESCRIPTION
OF OUR WARRANTS
This
section describes the general terms and provisions of our warrants to acquire our securities that we may issue from time to time. The
applicable prospectus supplement will describe the specific terms of the warrants offered through that prospectus supplement.
We
may issue warrants for the purchase of our debt securities, common stock or preferred stock or other securities issued by us. We may
issue warrants independently or together with other securities, and they may be attached to or separate from the other securities. We
will file a copy of the warrant and warrant agreement with the SEC each time we issue a series of warrants, and these warrants and warrant
agreements will be incorporated by reference into the Registration Statement of which this prospectus is a part. A holder of our warrants
should refer to the provisions of the applicable warrant agreement and prospectus supplement for more specific information.
The
applicable prospectus supplement will contain, where applicable, the following terms of and other information relating to the warrants:
| ● | the
specific designation and aggregate number of, and the price at which we will issue, the warrants; |
| ● | the
currency or currency units in which the offering price, if any, and the exercise price are
payable; |
| ● | the
designation, amount, and terms of the securities purchasable upon exercise of the warrants; |
| ● | if
applicable, the exercise price for shares of our common stock and the number of shares of
common stock to be received upon exercise of the warrants; |
| ● | if
applicable, the exercise price for shares of our preferred stock, the number of shares of
preferred stock to be received upon exercise and a description of that class or series of
our preferred stock; |
| ● | if
applicable, the exercise price for our debt securities, the amount of our debt securities
to be received upon exercise and a description of that series of debt securities; |
| ● | the
date on which the right to exercise the warrants will begin and the date on which that right
will expire or, if the warrants may not be continuously exercised throughout that period,
the specific date or dates on which the warrants may be exercised; |
| ● | whether
the warrants will be issued in fully registered form or bearer form, in definitive or global
form or in any combination of these forms, although, in any case, the form of a warrant included
in a unit will correspond to the form of the unit and of any security included in that unit; |
| ● | any
applicable material U.S. federal income tax consequences; |
| ● | the
identity of the warrant agent for the warrants and of any other depositaries, execution or
paying agents, transfer agents, registrars, or other agents; |
| ● | the
proposed listing, if any, of the warrants or any securities purchasable upon exercise of
the warrants on any securities exchange; |
| ● | if
applicable, the date from and after which the warrants and the common stock, preferred stock
or debt securities will be separately transferable; |
| ● | if
applicable, the minimum or maximum amount of the warrants that may be exercised at any one
time; |
| ● | information
with respect to book-entry procedures, if any; |
| ● | any
redemption or call provisions; |
| ● | whether
the warrants are to be sold separately or with other securities as parts of units; and |
| ● | any
additional terms of the warrants, including terms, procedures and limitations relating to
the exchange and exercise of the warrants. |
After
your warrants expire they will become void. All warrants will be issued in registered form. The prospectus supplement may provide for
the adjustment of the exercise price of the warrants.
Warrants
may be exercised at the appropriate office of the warrant agent, or any other office indicated in the applicable prospectus supplement.
Before the exercise of warrants, holders will not have any of the rights of holders of the securities purchasable upon exercise and will
not be entitled to payments made to holders of those securities.
The
warrant agreements may be amended or supplemented without the consent of the holders of the warrants to which it applies to effect changes
that are not inconsistent with the provisions of the warrants and that do not materially and adversely affect the interests of the holders
of the warrants. However, any amendment that materially and adversely alters the rights of the holders of warrants will not be effective
unless the holders of at least a majority of the applicable warrants then outstanding approve the amendment. Every holder of an outstanding
warrant at the time any amendment becomes effective, by continuing to hold the warrant, will be bound by the applicable warrant agreement
as amended. The prospectus supplement applicable to a particular series of warrants may provide that certain provisions of the warrants,
including the securities for which they may be exercisable, the exercise price and the expiration date, may not be altered without the
consent of the holder of each warrant.
Transfer
Agent and Registrar
The
transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement.
DESCRIPTION
OF OUR DEBT SECURITIES
This
section describes the general terms and provisions of the debt securities that we may offer under this prospectus, any of which may be
issued as convertible or exchangeable debt securities. We will set forth the particular terms of the debt securities we offer in a prospectus
supplement. The extent, if any, to which the following general provisions apply to particular debt securities will be described in the
applicable prospectus supplement. The following description of general terms relating to the debt securities and the indenture under
which the debt securities will be issued are summaries only and therefore are not complete. You should read the indenture and the prospectus
supplement regarding any particular issuance of debt securities.
We
will issue any debt under an indenture to be entered into between us and the trustee identified in the applicable prospectus supplement.
The terms of the debt securities will include those stated in the indenture and those made part of the indenture by reference to the
Trust Indenture Act of 1939, as amended (the “Indenture Act”), as in effect on the date of the indenture. We have filed or
will file a copy of the form of indenture as an exhibit to the Registration Statement in which this prospectus is included. The indenture
will be subject to and governed by the terms of the Indenture Act.
We
may offer under this prospectus up to an aggregate principal amount of $250,000,000 in debt securities, or if debt securities
are issued at a discount, or in a foreign currency, foreign currency units or composite currency, the principal amount as may be sold
for an initial public offering price of up to $250,000,000. Unless otherwise specified in the applicable prospectus supplement, the debt
securities will represent direct, unsecured obligations of the Company and will rank equally with all of our other unsecured indebtedness.
The
following statements relating to the debt securities and the indenture are summaries, qualified in their entirety by reference to the
detailed provisions of the indenture and the final form indenture as may be filed with a future prospectus supplement.
General
We
may issue the debt securities in one or more series with the same or various maturities, at par, at a premium, or at a discount. We will
describe the particular terms of each series of debt securities in a prospectus supplement relating to that series, which we will file
with the SEC.
The
prospectus supplement will set forth, to the extent required, the following terms of the debt securities in respect of which the prospectus
supplement is delivered:
| ● | the
title of the series; |
| ● | the
aggregate principal amount; |
| ● | the
issue price or prices, expressed as a percentage of the aggregate principal amount of the
debt securities; |
| ● | any
limit on the aggregate principal amount; |
| ● | the
date or dates on which principal is payable; |
| ● | the
interest rate or rates (which may be fixed or variable) or, if applicable, the method used
to determine such rate or rates; |
| ● | the
date or dates from which interest, if any, will be payable and any regular record date for
the interest payable; |
| ● | the
place or places where principal and, if applicable, premium and interest, is payable; |
| ● | the
terms and conditions upon which we may, or the holders may require us to, redeem or repurchase
the debt securities; |
| ● | the
denominations in which such debt securities may be issuable, if other than denominations
of $1,000 or any integral multiple of that number; |
| ● | whether
the debt securities are to be issuable in the form of certificated securities (as described
below) or global securities (as described below); |
| ● | the
portion of principal amount that will be payable upon declaration of acceleration of the
maturity date if other than the principal amount of the debt securities; |
| ● | the
currency of denomination; |
| ● | the
designation of the currency, currencies, or currency units in which payment of principal
and, if applicable, premium and interest, will be made; |
| ● | if
payments of principal and, if applicable, premium or interest, on the debt securities are
to be made in one or more currencies or currency units other than the currency of denomination,
the manner in which the exchange rate with respect to such payments will be determined; |
| ● | if
amounts of principal and, if applicable, premium and interest may be determined by reference
to an index based on a currency or currencies or by reference to a commodity, commodity index,
stock exchange index or financial index, then the manner in which such amounts will be determined; |
| ● | the
provisions, if any, relating to any collateral provided for such debt securities; |
| ● | any
addition to or change in the covenants and/or the acceleration provisions described in this
prospectus or in the indenture; |
| ● | any
events of default, if not otherwise described below under “Defaults and Notice”; |
| ● | the
terms and conditions, if any, for conversion into or exchange for shares of our common stock
or preferred stock; |
| ● | any
depositaries, interest rate calculation agents, exchange rate calculation agents or other
agents; and |
| ● | the
terms and conditions, if any, upon which the debt securities shall be subordinated in right
of payment to other indebtedness of the Company. |
We
may issue discount debt securities that provide for an amount less than the stated principal amount to be due and payable upon acceleration
of the maturity of such debt securities in accordance with the terms of the indenture. We may also issue debt securities in bearer form,
with or without coupons. If we issue discount debt securities or debt securities in bearer form, we will describe material U.S. federal
income tax considerations and other material special considerations which apply to these debt securities in the applicable prospectus
supplement.
We
may issue debt securities denominated in or payable in a foreign currency or currencies or a foreign currency unit or units. If we do,
we will describe the restrictions, elections, and general tax considerations relating to the debt securities and the foreign currency
or currencies or foreign currency unit or units in the applicable prospectus supplement.
Exchange
and/or Conversion Rights
We
may issue debt securities which can be exchanged for or converted into shares of our common stock or preferred stock. If we do, we will
describe the terms of exchange or conversion in the prospectus supplement relating to these debt securities.
Transfer
and Exchange
We
may issue debt securities that will be represented by either:
| ● | “book-entry
securities,” which means that there will be one or more global securities registered
in the name of a depositary or a nominee of a depositary; or |
| ● | “certificated
securities,” which means that they will be represented by a certificate issued in definitive
registered form. |
We
will specify in the prospectus supplement applicable to a particular offering whether the debt securities offered will be book-entry
or certificated securities.
Certificated
Debt Securities
If
you hold certificated debt securities issued under an indenture, you may transfer or exchange such debt securities in accordance with
the terms of the indenture. You will not be charged a service charge for any transfer or exchange of certificated debt securities but
may be required to pay an amount sufficient to cover any tax or other governmental charge payable in connection with such transfer or
exchange.
Global
Securities
The
debt securities of a series may be issued in the form of one or more global securities that will be deposited with a depositary or its
nominees identified in the prospectus supplement relating to the debt securities. In such a case, one or more global securities will
be issued in a denomination or aggregate denominations equal to the portion of the aggregate principal amount of outstanding debt securities
of the series to be represented by such global security or securities.
Unless
and until it is exchanged in whole or in part for debt securities in definitive registered form, a global security may not be registered
for transfer or exchange except as a whole by the depositary for such global security to a nominee of the depositary and except in the
circumstances described in the prospectus supplement relating to the debt securities. The specific terms of the depositary arrangement
with respect to a series of debt securities will be described in the prospectus supplement relating to such series.
No
Protection in the Event of Change of Control
Any
indenture that governs our debt securities covered by this prospectus may not have any covenant or other provision providing for a put
or increased interest or otherwise that would afford holders of our debt securities additional protection in the event of a recapitalization
transaction, a change of control of the Company or a highly leveraged transaction. If we offer any covenants or provisions of this type
with respect to any debt securities covered by this prospectus, we will describe them in the applicable prospectus supplement.
Covenants
Unless
otherwise indicated in this prospectus or the applicable prospectus supplement, our debt securities may not have the benefit of any covenant
that limits or restricts our business or operations, the pledging of our assets or the incurrence by us of indebtedness. We will describe
in the applicable prospectus supplement any material covenants in respect of a series of debt securities.
Consolidation,
Merger, and Sale of Assets
We
may agree in any indenture that governs the debt securities of any series covered by this prospectus that we will not consolidate with
or merge into any other person or convey, transfer, sell or lease our properties and assets substantially as an entirety to any person,
unless such person and such proposed transaction meets various criteria, which we will describe in detail in the applicable prospectus
supplement.
Defaults
and Notice
The
debt securities of any series will contain events of default to be specified in the applicable prospectus supplement, which may include,
without limitation:
| ● | failure
to pay the principal of, or premium or make-whole amount, if any, on any debt security of
such series when due and payable (whether at maturity, by call for redemption, through any
mandatory sinking fund, by redemption at the option of the holder, by declaration or acceleration
or otherwise); |
| ● | failure
to make a payment of any interest on any debt security of such series when due; |
| ● | our
failure to perform or observe any other covenants or agreements in the indenture with respect
to the debt securities of such series; |
| ● | certain
events relating to our bankruptcy, insolvency, or reorganization; and |
| ● | certain
cross defaults, if and as applicable. |
If
an event of default with respect to debt securities of any series shall occur and be continuing, we may agree that the trustee or the
holders of at least 25% in aggregate principal amount of the then outstanding debt securities of such series may declare the principal
amount (or, if the debt securities of such series are issued at an original issue discount, such portion of the principal amount as may
be specified in the terms of the debt securities of such series) of all debt securities of such series or such other amount or amounts
as the debt securities or supplemental indenture with respect to such series may provide, to be due and payable immediately. Any provisions
pertaining to events of default and any remedies associated therewith will be described in the applicable prospectus supplement.
Any
indenture that governs our debt securities covered by this prospectus may require that the trustee under such indenture shall, within
90 days after the occurrence of a default, give to holders of debt securities of any series notice of all uncured defaults with respect
to such series known to it. However, in the case of a default that results from the failure to make any payment of the principal of,
premium or make-whole amount, if any, or interest on the debt securities of any series, or in the payment of any mandatory sinking fund
installment with respect to debt securities of such series, if any, the trustee may withhold such notice if it in good faith determines
that the withholding of such notice is in the interest of the holders of debt securities of such series. Any terms and provisions relating
to the foregoing types of provisions will be described in further detail in the applicable prospectus supplement.
Any
indenture that governs our debt securities covered by this prospectus will contain a provision entitling the trustee to be indemnified
by holders of debt securities before proceeding to exercise any trust or power under the indenture at the request of such holders. Any
such indenture may provide that the holders of at least a majority in aggregate principal amount of the then outstanding debt securities
of any series may direct the time, method, and place of conducting any proceedings for any remedy available to the trustee, or of exercising
any trust or power conferred upon the trustee with respect to the debt securities of such series. However, the trustee under any such
indenture may decline to follow any such direction if, among other reasons, the trustee determines in good faith that the actions or
proceedings as directed may not lawfully be taken, would involve the trustee in personal liability or would be unduly prejudicial to
the holders of the debt securities of such series not joining in such direction.
Any
indenture that governs our debt securities covered by this prospectus may endow the holders of such debt securities to institute a proceeding
with respect to such indenture, subject to certain conditions, which will be specified in the applicable prospectus supplement and which
may include, that the holders of at least a majority in aggregate principal amount of the debt securities of such series then outstanding
make a written request upon the trustee to exercise its power under the indenture, indemnify the trustee and afford the trustee reasonable
opportunity to act. Even so, such holders may have an absolute right to receipt of the principal of, premium or make-whole amount, if
any, and interest when due, to require conversion or exchange of debt securities if such indenture provides for convertibility or exchangeability
at the option of the holder and to institute suit for the enforcement of such rights. Any terms and provisions relating to the foregoing
types of provisions will be described in further detail in the applicable prospectus supplement.
Modification
of the Indenture
We
and the trustee may modify any indenture that governs our debt securities of any series covered by this prospectus with or without the
consent of the holders of such debt securities, under certain circumstances to be described in a prospectus supplement.
Defeasance;
Satisfaction and Discharge
The
prospectus supplement will outline the conditions under which we may elect to have certain of our obligations under the indenture discharged
and under which the indenture obligations will be deemed to be satisfied.
Regarding
the Trustee
We
will identify the trustee and any relationship that we may have with such trustee, with respect to any series of debt securities, in
the prospectus supplement relating to the applicable debt securities. You should note that if the trustee becomes a creditor of the Company,
the indenture and the Indenture Act limit the rights of the trustee to obtain payment of claims in certain cases, or to realize on certain
property received in respect of any such claim, as security or otherwise. The trustee and its affiliates may engage in, and will be permitted
to continue to engage in, other transactions with us and our affiliates. If, however, the trustee acquires any “conflicting interest”
within the meaning of the Indenture Act, it must eliminate such conflict or resign.
Governing
Law
The
law governing the indenture and the debt securities will be identified in the prospectus supplement relating to the applicable indenture
and debt securities.
WHERE
YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE
We
file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website at www.sec.gov
that contains reports, statements, and other information about issuers, such as us, who file electronically with the SEC. We maintain
a website at www.abeonatherapeutics.com. However, the information on our website is not incorporated by reference into this prospectus
and any prospectus supplement and you should not consider it a part of this prospectus or any accompanying prospectus supplement.
The
SEC allows us to “incorporate by reference” into this prospectus the information in other documents that we file with it.
This means that we can disclose important information to you by referring you to those documents. The information incorporated by reference
is considered to be a part of this prospectus, and information in documents that we file later with the SEC will automatically update
and supersede information contained in documents filed earlier with the SEC or contained in this prospectus. We incorporate by reference
into this prospectus the documents listed below; provided, however, that we are not incorporating, in each case, any documents or information
deemed to have been furnished and not filed in accordance with SEC rules:
| ● | Our
Annual Report on Form
10-K for the year ended December 31, 2020; |
| ● | Our
Quarterly Report on Form
10-Q for the quarter ended March 31, 2021; |
| ● | Our
Current Reports on Form 8-K or 8-K/A filed on February
1, 2021, March
23, 2021, March
30, 2021, April
19, 2021, May
28, 2021 and May
28, 2021; and |
| ● | The
description of our common stock, par value $0.01 per share contained in our Registration
Statement on Form
8-A, dated and filed with the SEC on November 4, 2014, as updated by Exhibit
4.4 to our Form 10-K for the fiscal year ended December 31, 2019, and including any amendments
or reports filed with the SEC for the purpose of updating such description. |
All
reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination
of this offering, including all such documents we may file with the SEC after the date of this initial registration statement and prior
to the effectiveness of this registration statement, but excluding any information furnished to and not filed with, the SEC, will also
be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports
and documents.
You
may obtain a copy of any or all of the documents referred to above which may have been or may be incorporated by reference into this
prospectus, except for exhibits to those documents (unless the exhibits are specifically incorporated by reference into those documents)
at no cost to you by contacting us at the following address and telephone number: Investor Relations, Abeona Therapeutics Inc., 1330
Avenue of the Americas, 33rd Floor, New York, NY 10019, telephone (646) 813-4701.
LEGAL
MATTERS
Unless
otherwise specified in the prospectus supplement accompanying this prospectus, Morgan, Lewis & Bockius LLP will provide opinions
regarding certain legal matters. Certain partners and attorneys of Morgan, Lewis & Bockius LLP hold shares of our common stock. Additional
legal matters may be passed upon for us or any underwriters, dealers, or agents by counsel that we will name in the applicable prospectus
supplement.
EXPERTS
The
consolidated financial statements incorporated by reference from the Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2020 have been audited by Whitley Penn LLP, an independent registered public accounting firm, as stated in their report,
which is incorporated by reference into this prospectus. Such financial statements have been so incorporated in reliance upon the report
of such firm given upon their authority as experts in accounting and auditing.
3,284,407 Shares
of Common Stock
Pre-funded
warrants to purchase 2,919,140 Shares of Common Stock
PROSPECTUS SUPPLEMENT
Sole
Lead-Placement Agent
Cantor
Co-Placement Agent
A.G.P.
July 3, 2023
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Oct 2023 to Oct 2024